腹腔热灌注联合多西他赛、奥沙利铂静脉化疗治疗晚期卵巢癌疗效观察

发布时间：2018-04-13 08:55

本文选题：晚期卵巢癌 + 腹腔热灌注　；参考：《现代妇产科进展》2017年07期

【摘要】：目的:探讨肿瘤细胞减灭术(CRS)后腹腔热灌注联合多西他赛、奥沙利铂静脉化疗治疗晚期卵巢癌的临床疗效。方法:取2011年1月至2014年12月在河北医科大学第二医院就诊的晚期卵巢癌患者42例,其中观察组21例(CRS后+腹腔热灌注+多西他赛、奥沙利铂静脉化疗)、紫杉醇+卡铂组21例(CRS后+紫杉醇、卡铂静脉化疗)。比较两组的疗效、肿瘤控制、腹水控制、生活质量、治疗过程中的不良反应及并发症、无进展生存期(PFS)等。结果:观察组与对照组肿瘤控制差异无统计学意义(P0.05);腹水控制、生活质量、PFS均优于对照组,差异有统计学意义(P0.05)。不良反应及并发症无明显差异(P0.05)。结论:在临床上对于晚期卵巢癌患者采取CRS术后腹腔热灌注联合多西他赛、奥沙利铂静脉化疗,对于患者的疗效、肿瘤控制、腹水控制、生活质量、PFS有提高,且不明显增加不良反应及并发症。
[Abstract]:Objective: to investigate the clinical effect of intraperitoneal hyperthermic perfusion combined with docetaxel and oxaliplatin in the treatment of advanced ovarian cancer after CRS.Methods: from January 2011 to December 2014, 42 patients with advanced ovarian cancer were selected from the second Hospital of Hebei Medical University. Among them, 21 patients in the observation group received intraperitoneal hyperthermic infusion of docetaxel after CRS.Oxaliplatin intravenous chemotherapy, paclitaxel carboplatin group 21 cases after CRS paclitaxel, carboplatin intravenous chemotherapy.The efficacy, tumor control, ascites control, quality of life, adverse reactions and complications, progressive survival (PFS) were compared between the two groups.Results: there was no significant difference in tumor control between the observation group and the control group (P 0.05), while the control of ascites and the quality of life (PFS) were better than those in the control group (P 0.05).There was no significant difference in adverse reactions and complications (P 0.05).Conclusion: the efficacy, tumor control, ascites control and quality of life of patients with advanced ovarian cancer treated with intraperitoneal hyperthermic infusion combined with docetaxel and oxaliplatin after CRS were improved.There was no significant increase in adverse reactions and complications.
【作者单位】：河北医科大学第二医院妇科;河北医科大学第二医院神经外科;白求恩国际和平医院妇产科;河北医科大学第二医院肿瘤二科;
【基金】：河北省科技计划项目(No:152777220)
【分类号】：R737.31

【参考文献】